Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATX101 |
Synonyms | |
Therapy Description |
ATX101 is a peptide that targets PCNA, leading to decreased PCNA expression and inhibition of Akt and mTORC signaling, and potentially resulting in reduced tumor cell proliferation and inhibition of tumor growth (PMID: 35053455). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATX101 | ATX-101|ATX 101 | ATX101 is a peptide that targets PCNA, leading to decreased PCNA expression and inhibition of Akt and mTORC signaling, and potentially resulting in reduced tumor cell proliferation and inhibition of tumor growth (PMID: 35053455). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05116683 | Phase II | ATX101 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101) | Terminated | USA | 0 |